Countermeasure Efficacy Testing (Pharmaceutical & Nutraceutical)

The contract seeks to evaluate the protective effects of radioprotective compounds including NAC, Amifostine, Fisetin, and Metformin using a microphysiological system platform to assess their efficacy against radiation-induced damage. The work involves dose titration studies to determine optimal therapeutic concentrations and functional outcome assessments to measure biological responses, such as cell viability, tissue integrity, and physiological function following radiation exposure. This effort is focused on developing validated countermeasures for use in space environments where astronauts face increased risks from ionizing radiation. The contract is issued as a subcontract under the NASA Shared Services Center on behalf of the National Aeronautics and Space Administration, with performance expected to take place in Houston, Texas, 77058. It falls under the NAICS code 541690 for other scientific and technical consulting services and has a solicitation response deadline of July 6, 2026. The initiative is part of broader efforts to enhance crew safety during extended space missions by identifying and validating pharmaceutical and nutraceutical agents capable of mitigating radiation damage in human-relevant biological systems.